Medicare GLP-1 Coverage (2026)
The $50 Cap & CMS Bridge Program
2026 marks a monumental shift in how Medicare handles anti-obesity medications (AOMs). With new legislation capping out-of-pocket costs and expanding eligibility, millions of seniors now have access to GLP-1 therapies.
2026 Rollout Timeline
Eligibility vs. Coverage (2026)
| Medication | Indication Required for Medicare | Estimated Monthly Cost (Part D) |
|---|---|---|
| Ozempic | Type 2 Diabetes | $0 - $50 (Depending on plan)Best |
| Mounjaro | Type 2 Diabetes | $0 - $50 (Depending on plan) |
| Wegovy | Cardiovascular Risk + Obesity | Capped at $50/mo (Bridge Program) |
| Zepbound | Obesity (BMI > 30 with comorbidities) | Capped at $50/mo (Bridge Program) |
How the $50 Cap Works
Prior to 2026, patients on Medicare Part D often fell into the "donut hole," paying hundreds of dollars monthly for GLP-1s. The new legislation eliminates this gap.
If you are prescribed an FDA-approved GLP-1 for a covered indication, your maximum out-of-pocket cost is legally capped at $50 per month, contributing to a strict $2,000 annual maximum for all Part D drugs.
Steps to Get Approved
Guide FAQs
No. The law still prohibits Medicare from covering drugs strictly for cosmetic weight loss. However, the 2026 rules broadened the definition of "medical necessity" to include obesity when paired with a comorbidity like heart disease or sleep apnea.
It is a temporary funding mechanism designed to subsidize the cost of high-tier anti-obesity medications until generic or cheaper alternatives enter the market.
Track Your Health Metrics for Medicare PA
Shotlee allows you to easily export your weight loss progress and BMI history to share with your doctor for Prior Authorization renewals.